CLN-049, a novel FLT3/CD3 bispecific T-cell engager, has received fast track designation from the FDA for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML). 1 ...
The DOJ said the firm knowingly facilitated illicit trades tied to sex work, sanctions evasion, and fraud, earning millions ...
Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program focused on acute myeloid leukemia ...
RIA advocates are “very optimistic” that regulators will offer advisors a temporary reprieve (at the least) to comply with the Treasury Department’s forthcoming anti-money laundering rule, which is ...
Two of the largest organizations representing investment advisers and asset managers are voicing support for a federal proposal to postpone new anti-money laundering requirements for RIAs, while ...
The SEC emphasizes AML measures for low-priced securities in omnibus accounts, urging financial institutions to enhance due ...
Venclexta-azacitidine combination offered better responses with less hospitalization and lower symptom burden compared with ...
SEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on ...
– The Steering Committee brings together distinguished clinical experts in AML from leading National Comprehensive Cancer Network Centers – SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback